{"id":"W2768571810","doi":"10.1016/j.jtho.2017.11.023","title":"P2.04-010 Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Pembrolizumab; Stage (stratigraphy); Squamous-cell carcinoma of the lung; Basal cell; Oncology; Internal medicine; Lung; Cancer; Immunotherapy; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004990539,0.0005093762,0.001547596,0.0003152851,0.0003851582,0.0008141036,0.0005174988,0.0006944587,0.002762166],"category_scores_gemma":[0.0007607703,0.0002688171,0.0009216259,0.0004696487,0.0002592312,0.0007163137,0.0002546039,0.001480488,0.0006196001],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007830085,"about_ca_system_score_gemma":0.0008162584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001062622,"about_ca_topic_score_gemma":0.00399049,"domain_scores_codex":[0.9996992,0.00007707076,0.00003536302,0.00005958737,0.00004958071,0.00007921419],"domain_scores_gemma":[0.9997788,0.0000394584,0.00003720764,0.00001280051,0.00002977939,0.00010191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2176027,0.006147985,0.1014965,0.002111657,0.006769045,0.003479805,0.0004288834,0.005501012,0.06436459,0.001393264,0.02541346,0.5652911],"study_design_scores_gemma":[0.1867686,0.1574831,0.4788851,0.000900912,0.01302191,0.0183264,0.001313395,0.02229942,0.03155316,0.005302493,0.08373549,0.0004099978],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761632,0.01189136,0.00023814,0.00183526,0.0003885876,0.0001720505,0.0005892257,0.00009102025,0.008631076],"genre_scores_gemma":[0.9952388,0.001892969,0.0002450575,0.0004173755,0.00009580038,0.00006525117,0.0005592158,0.00001008057,0.001475567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002762166,"threshold_uncertainty_score":0.009240389,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01192178022171154,"score_gpt":0.3702795904329118,"score_spread":0.3583578102112002,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}